Eagle Pharmaceuticals, Inc. EGRX
OTC PK
| 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | |
|---|---|---|---|---|---|
| Net Income | -47.57% | -107.44% | 513.14% | 278.26% | -- |
| Total Depreciation and Amortization | 288.45% | 269.89% | 176.05% | 88.50% | -- |
| Total Amortization of Deferred Charges | -2.75% | -1.69% | -0.64% | 0.00% | -- |
| Total Other Non-Cash Items | -30.46% | -29.98% | -19.54% | 70.06% | -- |
| Change in Net Operating Assets | -327.09% | 102.04% | -272.00% | -481.02% | -- |
| Cash from Operations | -126.23% | 2,891.15% | 79.67% | -46.80% | -- |
| Capital Expenditure | 66.67% | 36.45% | 44.89% | 51.13% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 101.68% | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -150.00% | -150.00% | -- |
| Cash from Investing | 68.52% | -92,628.97% | -1,531.22% | -1,495.70% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -971.70% | -731.08% | -740.45% | 0.00% | -- |
| Issuance of Common Stock | -89.21% | 121.14% | -36.54% | -56.49% | -- |
| Repurchase of Common Stock | 57.35% | 62.38% | 16.35% | -29.17% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 137.20% | 148.45% | 78.13% | 23.29% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 70.61% | -33.38% | -670.34% | -938.54% | -- |